Corline Biomedical (CLBIO) Q4 2025 earnings summary

Executive summary

• Achieved key milestone with first commercial use of CHS™ in a US-launched product, driving entry into the fast-growing PFA market for cardiac arrhythmia treatment.

• Strategic focus on scaling production and strengthening partnerships, notably with Kardium, to support anticipated volume growth and customer activity in 2026.

Financial highlights

• Net sales for Q4 2025 were 2,104 KSEK, up slightly from 2,012 KSEK in Q4 2024; full-year net sales were 7,651 KSEK, down from 9,775 KSEK year-over-year.

• Q4 result after financial items was -5,027 KSEK (improved from -14,161 KSEK); full-year result after financial items was -14,714 KSEK (improved from -23,194 KSEK).

• No one-time items affected 2025 results, compared to -9,992 KSEK in 2024.

• Cash and cash equivalents at year-end were 20.6 MSEK, up from 17.7 MSEK.

• Equity at year-end was 93,759 KSEK, with a solidity of 95%.

Outlook and guidance

• Expecting volume growth and increased customer activity in 2026, supported by commercial agreements and regulatory tailwinds in the US.

• Ongoing investments in production capacity and quality systems to meet future demand and regulatory requirements.